Healthcare
Vincerx Pharma, Inc.(VINC)
Live Price
Offline$0.013
+0.00% today
1Y Change
-75.47%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- โ
- Revenue Growth
- 0.0%
- EPS Growth
- +15.9%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vincerx Pharma, Inc. (VINC) is a Healthcare stock with listed on OTC. The stock last traded around $0.01 and down 75.5% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +15.9%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +15.9%, free cash flow +35.4% with operating margin -1138.6% and ROIC -588.6%. Valuation is more restrained than many high-expectation growth names at price/sales 0.1. Stock Foundry combines VINC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
-1138.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +15.9%, while operating margin sits near -1138.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +33.3% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | +30.8% | +0.0% | +0.0% |
2026 Mar 27, 2026 | โ | +0.0% | +0.0% | +0.0% |
2025 Nov 10, 2025 | โ | +0.0% | +100.0% | +140.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VINC
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VINC Max Drawdown
-92.42%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VINC and SPY.
Company Overview
Vincerx Pharma, Inc.
Other OTC
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
- Leadership
- Raquel E. Izumi
- IPO Date
- May 27, 2020
- Employees
- 12
- Street Address
- 260 Sheridan Avenue
- Mailing
- Palo Alto, CA, 94306
- Region
- Palo Alto, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 800 6676
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.4
- Price/Sales
- 0.1
- Price/Book
- 0.0
Growth
- Revenue
- 0.0%
- EPS
- +15.9%
- Free Cash Flow
- +35.4%
Profitability
- Gross Margin
- 50.0%
- Operating Margin
- -1138.6%
- Net Margin
- -1216.7%
- ROE
- -542.5%
- ROIC
- -588.6%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 1.79
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.